Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Art of Investing -- Ignore unavailable to you. Want to Upgrade?

To: Sun Tzu who wrote (10531)	11/6/2025 7:30:09 PM
From: Sun Tzu	Respond to of 10711

Cerus Corporation Announces Record Results for Third Quarter 2025 Nov 6, 2025, 16:05 GMT-52 min read CERS-2.76% Cerus Corporation has reported its financial results for the third quarter ended September 30, 2025, showcasing significant growth and operational achievements. The company, dedicated to safeguarding the world's blood supply, has seen a notable increase in revenue and has raised its full-year product revenue guidance. Financial Highlights For the third quarter of 2025, Cerus Corporation reported a total revenue of $60.2 million, marking a 19% increase from the $50.7 million reported in the same period of 2024. Product revenue reached a record $52.7 million, up 15% year-over-year, driven by strong global commercial execution and growing awareness of the INTERCEPT Blood System. Government contract revenue also saw a significant rise, increasing by 63% to $7.5 million. The company's GAAP net loss narrowed to $0.02 million, nearly breakeven, compared to a net loss of $2.9 million in the prior year period. Non-GAAP adjusted EBITDA for the third quarter was $5.0 million, up from $4.4 million in the same period of 2024. Business and Operational Highlights Hospital demand for INTERCEPT Fibrinogen Complex (IFC) in the U.S. continues to grow, with third-quarter volumes up approximately 110% compared to the prior year period. U.S. IFC sales totaled $3.9 million, up from $2.3 million during the prior year period. Additionally, Cerus completed enrollment in the U.S. RedeS trial, a pivotal Phase 3 clinical trial evaluating the safety and efficacy of red blood cells prepared with the INTERCEPT Blood System for Red Blood Cells (RBCs). Strategic Initiatives and Corporate Developments Cerus has raised its full-year 2025 product revenue guidance to a range of $202 million to $204 million, reflecting growth of 12% to 13% from 2024. This includes full-year 2025 IFC revenue guidance between $16 million to $17 million. The company also reported cash, cash equivalents, and short-term investments of $78.5 million as of September 30, 2025. Management's Perspective William “Obi” Greenman, Cerus’ president and chief executive officer, commented on the results, stating, “We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System.” Future Outlook The company expects full-year 2025 product revenue to be in the range of $202 million to $204 million, with IFC revenue guidance between $16 million to $17 million. Cerus is also well positioned to achieve its goal of positive full-year 2025 non-GAAP adjusted EBITDA. Original SEC Filing: CERUS CORP [ CERS ] - 8-K - Nov. 06, 2025 Disclaimer This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.